Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Makers Want Say In Medicare 'Coverage-With-Evidence-Development' Policy

This article was originally published in The Gray Sheet

Executive Summary

Manufacturers seek more input on trial designs and objectives when CMS takes the "coverage-with-evidence-development" route to national Medicare coverage.

You may also be interested in...



Minimally Invasive Spine Technique Gets Second Look By CMS

The Medicare agency is reconsidering coverage of percutaneous image-guided lumbar decompression for lumbar spine stenosis in response to a request by device manufacturer Vertos. The firm's goal is to lift current clinical trial conditions for coverage of the procedure.

CMS Ambiguous On Role Of Local Contractors In Coverage With Evidence Development

Activities by Medicare contractors were among several matters that were addressed in CMS’ recent CED draft guidance that may not be fully clarified until the updated guidelines are put into practice, experts say.

A “Fine Line:” CMS’ Jacques On Coverage-With-Evidence Requirements

Medicare coverage director Louis Jacques describes the necessary balancing act to gauge the appropriate level of data requirements for a coverage-with-evidence-development policy.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel